Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05506254 · ClinicalTrials.gov registry record
Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy
A clinical trial of Methylmalonic Acidemia, sponsored by Alexion Pharmaceuticals.
- Active
- Registry status
- 4
- Enrollment target
- 4
- Study locations
NCT05506254: Active study of Methylmalonic Acidemia, sponsored by Alexion Pharmaceuticals.
NCT05506254 is a study of Methylmalonic Acidemia that is active but no longer recruiting, run by Alexion Pharmaceuticals. The registered enrollment target is 4 participants, below the 426-participant average among 6 other Methylmalonic Acidemia trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05506254, a study of Methylmalonic Acidemia, is active but no longer recruiting, sponsored by Alexion Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- 4 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a non-interventional long-term follow-up study of patients who have participated in LogicBio studies for the treatment of MMA and received hLB-001
Conditions Studied
Interventions
- DRUG hLB-001
Study Locations (4)
Georgia
- Clinical Trial Site - Atlanta
Pennsylvania
- Clinical Trial Site - Pittsburgh
Tennessee
- Clinical Trial Site - Nashville
Washington
- Clinical Trial Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-07-15 |
| Est. Completion | 2037-01-01 |
What the registry record for NCT05506254 still lists
NCT05506254 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 426-participant average among 6 other Methylmalonic Acidemia trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Methylmalonic Acidemia appearing as the primary indexed condition, and to 1 intervention - of which hLB-001 is the first listed.
NCT05506254 reports a single indexed study location in Georgia, Pennsylvania, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05506254 about?
NCT05506254 is a clinical study titled "Long-term Follow-up Study of Patients Who Received hLB-001 Gene Therapy". This is a non-interventional long-term follow-up study of patients who have participated in LogicBio studies for the treatment of MMA and received hLB-001
What is the current status of trial NCT05506254?
This trial is currently active not recruiting. The enrollment target is 4 participants. The study started on 2022-07-15. Estimated completion is 2037-01-01.
What conditions does trial NCT05506254 study?
This clinical trial studies the following conditions: Methylmalonic Acidemia.
What interventions are being tested in trial NCT05506254?
The interventions under investigation include: hLB-001 (DRUG).
Who is sponsoring clinical trial NCT05506254?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05506254 being conducted?
This trial has 4 study locations across Georgia, Pennsylvania, Tennessee, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Methylmalonic Acidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705
RECRUITING · Phase 1
-
An Observational Study of Carbaglu® for the Treatment of MMA and PA in Adults and Pediatrics
RECRUITING
-
Clinical and Laboratory Study of Methylmalonic Acidemia
RECRUITING
-
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia
ACTIVE NOT RECRUITING · Phase 1
-
"The MaP Study": Mapping the Patient Journey in MMA and PA
COMPLETED
-
Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI